Evidence map›Paper›PMID 33810278›Full record

ArticleNanomaterials (Basel, Switzerland)2021

MIL-101(Cr), an Efficient Heterogeneous Catalyst for One Pot Synthesis of 2,4,5-tri Substituted Imidazoles under Solvent Free Conditions.

Faranak Manteghi, Fatemeh Zakeri, Owen James Guy, Zari Tehrani

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 23 citations in OpenAlex.

  1. FeACS omega · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Faranak ManteghiResearch Laboratory of Inorganic Chemistry and Environment, Department of Chemistry, Iran University of Science and Technology, Narmak, Tehran 1684613114, Iran.
Fatemeh ZakeriResearch Laboratory of Inorganic Chemistry and Environment, Department of Chemistry, Iran University of Science and Technology, Narmak, Tehran 1684613114, Iran.
Owen James GuyDepartment of Chemistry, College of Science, Swansea University, Singleton Park, Swansea SA2 8PP, UK.ORCID 0000-0002-6449-4033
Zari TehraniCentre for NanoHealth, College of Engineering, Institute of Life Science-2, Swansea University, Singleton Park, Swansea SA2 8PP, UK.
Iran University of Science and Technology · IRSwansea University · GB

Funding

European Regional Development Fund 80761-su-100H2020 Marie Skłodowska-Curie Actions 663830Iran University of Science and Technology 17652
6 · The paper itself

Abstract

A chromium-containing metal-organic framework (MOF), MIL-101 (Chromium(III) benzene-1,4-dicarboxylate), was used to catalyze the one pot, three component synthesis of some 2,4,5-trisubstituted imidazoles under solvent-free conditions. The advantages of using this heterogeneous catalyst include short reaction time, high yields, easy and quick isolation of catalyst and products, low amount of catalyst needed, and that the addition of solvent, salt, and additives are not needed. This catalyst is highly efficient and can be recovered at least 5 times with a slight loss of efficiency. The structure of the metal-organic frameworks (MOF) was confirmed by X-ray diffraction (XRD) and field emission scanning electron microscopy (FESEM). Fourier transform infrared spectroscopy (FTIR) and proton nuclear magnetic resonance (HNMR) were performed to confirm some of the synthesized products. Experimental data indicated that the optimum amount of catalyst was 5 mg for benzil (1 mmol), 4-chlorobenzaldehyde (1 mmol), and ammonium acetate (2.5 mmol), and the synthetic route to the various imidazoles is performed in 10 min by 95% yield, an acceptable result rivalling those of other catalysts.

Indexed as

heterogeneous catalysismetal-organic frameworksMIL-101multicomponent reactionssolvent free

Identifiers

PMID33810278
PMCPMC8067193
OpenAlexW3147030545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.